State coverage
Oklahoma Medicaid and GLP-1 coverage
Medicaid, for obesity: Other diagnoses only. The conditions are in the summary below, along with why no appeal deadline could be published for this state.
At a glance
- Medicaid, for obesity
- Calls the category adiposity-based chronic disease, then closes the obesity-alone door three times over.
- Appeal deadline
- Not published here. Oklahoma's official rules sit on a host that refuses every request, and the agency says its own online copies are unofficial — so the filing window could not be read from the document that binds you. Go by the date on your notice. Federal ceiling: no more than 90 days.
- Date read
- September 2026
Oklahoma does not have a weight-loss drug category. It has one called Adiposity-Based Chronic Disease, and that is not a euphemism — it changes how the criteria are written.
Framing obesity as a chronic disease would normally point toward broader coverage. Here it does the opposite. Each drug gets its own indication and each one carries the same sentence, in slightly different words, saying it will not be approved for an obese member who does not also have the other condition. Wegovy needs established cardiovascular disease or liver disease. Zepbound needs sleep apnea. The state writes that door shut three separate times.
There is one real weight-management route, and it is narrow. Imcivree is covered for chronic weight management from age two, but only for obesity caused by named genetic conditions, confirmed by genetic testing submitted with the request.
Oklahoma also publishes less than it looks like it does. Its rules are on a site that will not answer, and the copies on its own website say on every page that they are unofficial — so there is no appeal deadline on this page.
What we could verify for Oklahoma
Oklahoma files these drugs under a disease name rather than a weight-loss one. Its 2026 criteria page for the class is headed "Metabolic Disorders" and the section itself "Adiposity-Based Chronic Disease (ABCD) Medications", covering Imcivree, Wegovy and Zepbound. The page is stamped "Last Modified on Aug 17, 2026".
Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 · source
Zepbound is a sleep apnea drug here, and the criteria say so twice over: "An FDA approved indication of moderate to severe OSA in members with obesity; and Zepbound® will not be approved for obese members in the absence of OSA" — the source runs straight on into the next condition It also requires an AHI of at least 15 on a sleep study, a BMI of at least 30, no central or mixed sleep apnea, and that the "Member does not have type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM)" with "a hemoglobin A1C (HbA1c) <6.5%".
Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 · source
Wegovy has two doors and both shut on obesity alone. For heart risk the criteria require established cardiovascular disease and state that Wegovy "will not be approved for obese or overweight members in the absence of established CVD", with the member "45 years of age or older". For liver disease they state it "will not be approved for obese members in the absence of MASH", with fibrosis confirmed by FibroScan, an Enhanced Liver Fibrosis score or a biopsy.
Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 · source
One genuine weight-management route survives and it is genetic. Imcivree is approved for "chronic weight management in adult and pediatric members 2 years of age and older with obesity due to" POMC, PCSK1 or leptin receptor deficiency, or Bardet-Biedl syndrome — each confirmed by "molecular genetic testing" whose results "must be submitted" with the request.
Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 · source
Oklahoma tells you itself that the rules on its website are not the rules. Every OHCA policy page carries the line: "The OHCA rules found on this Web site are unofficial. The official rules are published by the Oklahoma Secretary of State Office of Administrative Rules as Title 317 of the Oklahoma Administrative Code." That official site, rules.ok.gov, answered 403 to every attempt in this session, including with a full browser fingerprint, while other state sites answered normally — so the binding text of the appeal rule could not be read from its publisher.
Oklahoma Health Care Authority, Policies and Rules — Administrative Appeals · source
Oklahoma is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. Oklahoma Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Oklahoma with the rest in the coverage matrix.
If you work for the State of Oklahoma
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: HealthChoice (Employees Group Insurance Division, OMES). Its pharmacy benefit runs through CVS Caremark.
Certain weight loss drugs excluded; Wegovy not listed
HealthChoice's handbook excludes certain weight loss drugs and appetite suppressants, and its July 2026 drug list doesn't list Wegovy or Zepbound. GLP-1s for type 2 diabetes, like Ozempic and Mounjaro, stay covered through CVS Caremark, with a diabetes check.
The HealthChoice handbook's drug exclusions list "Certain weight loss drugs." and its personal care exclusions add "Appetite suppressants."
Oklahoma Employees Group Insurance Division, HealthChoice Health Plans Handbook, Plan Year 2025, effective January 2025 · source
Under "Services Your Plan Does NOT Cover" the 2026 HealthChoice Basic summary lists "Weight loss programs" and, under other covered services, "Bariatric surgery".
Oklahoma EGID, Summary of Benefits and Coverage, HealthChoice Basic, coverage period 01/01/2026 - 12/31/2026, effective January 2026 · source
"HealthChoice provides you with a prescription benefits administered by CVS Caremark®." The July 2026 HealthChoice Standard Medication List does not list Wegovy, Zepbound or Saxenda.
CVS Caremark, HealthChoice Standard Medication List, effective July 2026 · source
For the State of Oklahoma, Caremark pays diabetes GLP-1s such as Ozempic and Mounjaro automatically "If a claim is submitted with an ICD 10 diagnosis code indicating type 2 diabetes mellitus"; otherwise "the claim will reject with a message indicating that a prior authorization (PA) is required."
CVS Caremark, Prior Authorization Criteria, Antidiabetic GLP-1 GIP-GLP-1 Agonist PA with Logic, State of Oklahoma (C28922-D), effective December 2024 · source
If the appeal fails, or you cannot wait
Oklahoma Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerEdenCheck availability | Semaglutide at $99 a month at every dose, with no membership on the page our link opens. Eden's own site pairs the same $99 with a required membership ($39 the first month, then $99), so check which one you're signing up for. |
| PartnerShedRxCheck availability | Injections plus needle-free drops and lozenges. You see a price only after the questionnaire, and the oral forms aren't sold in sixteen states. |
| PartnerHealthRXCheck availability | Compounded semaglutide at $133 a month on a three-month plan ($99 on twelve), tirzepatide from $209 ($179 on twelve). Its member reviews are labeled illustrative composites, not real patients. |
| PartnerMEDGmCheck availability | GLP-1 injections from $179 and tablets from $249. Brand options are a membership plus the drug's own cost: $99 for Zepbound or Wegovy, $171 for Ozempic. It discloses AI content and actor imagery. |
| PartnerBodybuilding Health+Check availability | Compounded tirzepatide at $174.67 to $209 a month, lower the more months you buy at once; semaglutide is tiered the same way. Operated by Dynamo Group LLC. |
| PartnerStrut HealthCheck availability | A telehealth storefront where weight loss is one of six categories. No GLP-1 price is published on the page our link opens. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, and they change often. Check the current number before you buy.
Where this comes from
- Oklahoma Health Care Authority, Prior Authorization Criteria 2026 — Metabolic Disorders, effective August 2026 — oklahoma.gov/ohca/providers/types/pharmacy/prior-authorization/2026/meta
- Oklahoma Health Care Authority, Policies and Rules — Administrative Appeals — oklahoma.gov/ohca/policies-and-rules/xpolicy/grievance-procedures-and-pr